Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher M Blanchette

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Journal of Medical Economics|October 11, 2017
The value of self-medication: summary of existing evidenceJoshua Noone, Christopher M Blanchette
Annals of Internal Medicine|March 5, 2014
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney diseaseChristopher M Blanchette, Benjamin Gutierrez, Keith Friend
Journal of Medical Economics|July 21, 2012
Changes in COPD demographics and costs over 20 yearsChristopher M Blanchette, Anand A Dalal, Douglas Mapel
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 27, 2007
Influence of medication treatment patterns on resource use for patients hospitalized for schizophreniaDavid R Strutton, Benjamin Gutierrez, Christopher M Blanchette
American Health & Drug Benefits|July 4, 2014
Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the TrendChristopher M Blanchette, Nicholas J Gross, Pablo Altman
Journal of Health Economics and Outcomes Research|May 27, 2022
The Association of COPD Exacerbations with New Onset Type 2 Diabetes among Medicare PatientsJoseph S Marino, Cynthiya Ruban, Christopher M Blanchette
Current Opinion in Pulmonary Medicine|December 24, 2010
Advances in chronic obstructive pulmonary disease among older adultsChristopher M Blanchette, Susan R Berry, Sandi J Lane
Clinical Therapeutics|January 30, 2010
Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthmaChristopher M Blanchette, Steven D Culler, Daniel Ershoff, et al.
Drugs in Context|January 17, 2014
Probabilistic data linkage: a case study of comparative effectiveness in COPDChristopher M Blanchette, Mitch Dekoven, Ajita P De, et al.
The American Journal of Geriatric Pharmacotherapy|September 9, 2008
Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adultsChristopher M Blanchette, Manabu Akazawa, Anand Dalal, et al.
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Journal of Medical Economics|October 11, 2017
The value of self-medication: summary of existing evidenceJoshua Noone, Christopher M Blanchette
Annals of Internal Medicine|March 5, 2014
Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney diseaseChristopher M Blanchette, Benjamin Gutierrez, Keith Friend
Journal of Medical Economics|July 21, 2012
Changes in COPD demographics and costs over 20 yearsChristopher M Blanchette, Anand A Dalal, Douglas Mapel
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 27, 2007
Influence of medication treatment patterns on resource use for patients hospitalized for schizophreniaDavid R Strutton, Benjamin Gutierrez, Christopher M Blanchette
American Health & Drug Benefits|July 4, 2014
Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the TrendChristopher M Blanchette, Nicholas J Gross, Pablo Altman
Journal of Health Economics and Outcomes Research|May 27, 2022
The Association of COPD Exacerbations with New Onset Type 2 Diabetes among Medicare PatientsJoseph S Marino, Cynthiya Ruban, Christopher M Blanchette
Current Opinion in Pulmonary Medicine|December 24, 2010
Advances in chronic obstructive pulmonary disease among older adultsChristopher M Blanchette, Susan R Berry, Sandi J Lane
Clinical Therapeutics|January 30, 2010
Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthmaChristopher M Blanchette, Steven D Culler, Daniel Ershoff, et al.
Drugs in Context|January 17, 2014
Probabilistic data linkage: a case study of comparative effectiveness in COPDChristopher M Blanchette, Mitch Dekoven, Ajita P De, et al.
The American Journal of Geriatric Pharmacotherapy|September 9, 2008
Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adultsChristopher M Blanchette, Manabu Akazawa, Anand Dalal, et al.
Pageof 8